

Lilly

A MEDICINE COMPANY

ELI LILLY AND COMPANY
Q3 2025 EARNINGS CALL



Agenda

Introduction and Key Events

Dave Ricks, Chair and Chief Executive Officer

Q3 2025 Financial Results

Lucas Montarce, Chief Financial Officer

R&D Update

Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Question & Answer Session

Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Q3 2025 Summary

Deliver Revenue Growth

Delivered robust **revenue growth of 54%** driven by **Key Products**¹

Lilly U.S. incretin analogs **share of market** increased to **57.9%** of total prescriptions, with **market growth of 36%** versus prior year

Raised midpoint of full year revenue guidance by over **\$2 billion**

Invest in Future Innovation

Announced **significant investments in manufacturing, including new facilities** in Virginia and Texas and **expansion of an existing facility** in Puerto Rico

Announced **partnership with NVIDIA** to **accelerate drug discovery**

Opened new **Lilly Gateway Labs** in San Diego

Speed Life-Changing Medicines

U.S. FDA **approved Inluriyo (imlunestrant)** in ER+, HER2-, ESR1 mutated advanced or metastatic breast cancer

Kisunla **received marketing authorization in Europe** for early symptomatic Alzheimer's disease

Orforglipron positive results in **four additional Phase 3 trials**

Jaypirca **significantly improved progression free survival** in treatment-naïve CLL/SLL

¹ Key products include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound
Note: Revenue growth rates reflect change vs. Q3 2024

Strategic Deliverables

Deliver Revenue Growth			Invest in Future Innovation		Invest in Current Portfolio
TOTAL REVENUE	\$17.6B	54% ↑	RESEARCH & DEVELOPMENT	CAPITAL INVESTMENTS (YTD)	MARKETING, SELLING & ADMINISTRATIVE
			\$3.5B	\$5.3B	\$2.7B 31% ↑
			27% ↑	49% ↑	
KEY PRODUCT REVENUE	\$12.0B	104% ↑			NON-GAAP EARNINGS PER SHARE
					\$7.02 +\$5.84

Speed Life-Changing Medicines		
APPROVALS / LAUNCHES		STUDY RESULTS
- Inluriyo (imlunestrant) approved in the U.S. for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer - Kisunla approved in the EU for early symptomatic Alzheimer’s disease	 	- Jaypirca significantly improved progression-free survival in treatment-naïve CLL/SLL - Verzenio prolonged survival in HR+, HER2- high-risk early breast cancer - Orforglipron was successful in second obesity trial, triggering global regulatory submission in 2025 for the treatment of obesity - Orforglipron superior to oral semaglutide and dapagliflozin in two H2H Phase 3 trials

Return Capital to Shareholders		
	\$1.3B	DISTRIBUTED VIA DIVIDENDS
	\$0.7B	DISTRIBUTED IN SHARE REPURCHASES

Note: Total revenue, key product revenue, research and development, marketing, selling and administrative, and Non-GAAP EPS growth rates reflect change vs. Q3 2024



Q3 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

Q3 2025

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	\$17,601	\$ -	\$17,601	54%
GROSS MARGIN	82.9%	0.7 pp	83.6%	1.4pp
TOTAL OPERATING EXPENSE	\$7,227	\$ (365)	\$6,862	(10)%
OPERATING INCOME	\$7,365	\$485	\$7,850	NM
OTHER INCOME (EXPENSE)	\$(133)	\$(48)	\$(181)	NM
EFFECTIVE TAX RATE	22.8%	(5.1) pp	17.7%	(19.9)pp
NET INCOME	\$5,583	\$729	\$6,312	NM
EPS	\$6.21	\$0.81	\$7.02	NM
Acquired IPR&D Charge per share¹	\$0.71	\$ -	\$0.71	(77)%

¹ Acquired IPR&D (in-process research and development) charge of \$656 million (pre-tax). Numbers may not add due to rounding; NM = not meaningful

Performance Margin²	45.6%	48.3%	+8.3pp
---------------------------------------	--------------	--------------	---------------

² The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue

Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 20

Price/Rate/Volume Effect on Revenue

Dollars in millions

Q3 2025

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	\$11,300	(15)%	-	60%	45%	45%
EUROPE	\$3,498	6%	10%	98%	115%	104%
JAPAN	\$555	0%	5%	24%	29%	24%
CHINA	\$560	0%	0%	21%	22%	22%
REST OF WORLD	\$1,688	(1)%	1%	53%	52%	51%
TOTAL REVENUE	\$17,601	(10)%	2%	62%	54%	52%

Dollars in millions


YTD 2025

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	\$30,604	(11)%	-	54%	43%	43%
EUROPE	\$8,461	(1)%	4%	86%	89%	85%
JAPAN	\$1,478	(0)%	2%	16%	18%	15%
CHINA	\$1,477	1%	(1)%	19%	20%	21%
REST OF WORLD	\$3,867	(0)%	(2)%	22%	21%	22%
TOTAL REVENUE	\$45,887	(7)%	0%	52%	46%	45%

Numbers may not add due to rounding

CER = price change + volume change

Q3 2025 Update on Key Products



Key Product Highlights:

- MOUNJARO**
Gained U.S. type 2 diabetes incretin analogs SOM leadership with TRx SOM 45% and NBRx SOM 54% at end of Q3 2025


Increased U.S. TRx and NBRx share by 4pp each vs. end of Q2 2025

International revenue grew 56% vs. Q2 2025
- ZEPBOUND**
U.S. branded anti-obesity TRx SOM 63% and NBRx SOM 71% at end of Q3 2025

TRx share decreased by 2pp vs. end of Q2 2025 driven by CVS excluding Zepbound from template plans

NBRx share increased by 4pp vs. end of Q2 2025 with new patient starts rebounding post CVS template plans access change
- VERZENIO**
U.S. TRx grew 3% vs. Q3 2024
International volume grew 14% vs. Q3 2024
- JAYPIRCA**
Q3 2025 sales of \$143M; U.S. TRx increased 61% vs. Q3 2024
- EBGLYSS**
Q3 2025 sales of \$127M; U.S. TRx grew 41% vs. Q2 2025
- OMVOH**
Q3 2025 sales of \$65M; first IL-23p19 to show 4-year data in UC supporting long-term safety and benefit of continuous treatment
- KISUNLA**
Q3 2025 sales of \$70M; received marketing authorization by European Commission

U.S. Incretin Analogs Market



Incretin Analogs Market Key Highlights:

U.S. market grew 36% in Q3 vs. prior year and 7% vs. Q2 2025

Lilly share of market increased to 57.9%, +1.0pp vs. prior quarter, despite Zepbound CVS template plans access change on 7/1/25


Lilly’s NBRx share of market increased to 65.1%, +1.3pp

Source: IQVIA weekly NPA total prescriptions, weekly data September 26, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

Capital Allocation

\$ in billions

YTD 2025 Capital Allocation



* After tax

** Includes development milestones, closed acquisitions and cash outflows associated with equity investments

2025 Guidance

	Prior	Updated	Comments
REVENUE	\$60.0 – \$62.0 billion	\$63.0 – \$63.5 billion	Strong underlying business performance and updated foreign exchange rate expectations
PERFORMANCE MARGIN¹			
(GAAP)	42.0% – 43.5%	43.5% – 44.5%	Increased to reflect updated revenue expectations
(NON-GAAP)	43.0% – 44.5%	45.0% – 46.0%	
OTHER INCOME/(EXPENSE)			
(GAAP)	\$(750) – \$(650) million	\$(700) – \$(600) million	Decrease in net losses on investments in equity securities
(NON-GAAP)	\$(700) – \$(600) million	Unchanged	
TAX RATE			
(GAAP)	Approx. 19%	Unchanged	
(NON-GAAP)	Approx. 17%	Unchanged	
EARNINGS PER SHARE²			
(GAAP)	\$20.85 – \$22.10	\$21.80 – \$22.50	
(NON-GAAP)	\$21.75 – \$23.00	\$23.00 – \$23.70	


¹ The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative and asset impairment, restructuring and other special charges divided by revenue

² 2025 assumes shares outstanding of approximately 899.3 million

FX assumptions of 1.14 (Euro), 149 (Yen) and 7.1 (Yuan)

Orforglipron ATTAIN-2 Topline Results

People with type 2 diabetes and obesity



Key Highlights:

Orforglipron met the primary and all key secondary endpoints, demonstrating compelling efficacy

The safety and tolerability of orforglipron was consistent with injectable GLP-1 medicines

Lilly now has full clinical data package to initiate global regulatory submissions for orforglipron in obesity


Note: Efficacy Estimand Results; Superiority test was adjusted for multiplicity with all three orforglipron doses



Orforglipron ACHIEVE-3 Topline Results

People with type 2 diabetes

Body Weight Change at 52 Weeks



BASELINE WEIGHT: 97.0 kg


Oral Semaglutide
7 mg

Oral Semaglutide
14 mg

Orforglipron
12 mg

Orforglipron
36 mg

A1C Change at 52 Weeks



BASELINE A1C: 8.3%

Key Highlights:

Orforglipron was superior to oral semaglutide in a H2H trial in adults with type 2 diabetes

Orforglipron 36 mg helped nearly three times as many participants reach near-normal A1C versus oral semaglutide 14 mg

The safety and tolerability of orforglipron was consistent with injectable GLP-1 medicines

Anticipated global regulatory submission for T2D in 1H 2026, pending completion of ACHIEVE-4

Note: Efficacy Estimand Results; Body weight for orforglipron 12 mg vs. oral semaglutide 14 mg was not controlled for family-wise type 1 error

Upcoming Key Events in Cardiometabolic Health

Orforglipron

TYPE 2 DIABETES

Completion: Q1 2026
Submission: 1H 2026

ACHIEVE-1 ✓
ACHIEVE-2 ✓
ACHIEVE-3 ✓

ACHIEVE-4
ACHIEVE-5 ✓

OBESITY

Completion: Q3 2025

ATTAIN-1 ✓

ATTAIN-2 ✓

WEIGHT MAINTENANCE

ATTAIN-MAINTAIN
Completion: 2025/2026

OSA

ATTAIN-OSA
Completion: 2027

HYPERTENSION

ATTAIN-OSA
Completion: 2027

OA KNEE PAIN

ATTAIN-OA PAIN
Completion: 2027

Retatrutide

TYPE 2 DIABETES

Completion: 2027

TRANSCEND-1
TRANSCEND-2
TRANSCEND-3

OBESITY, OA & OSA

Completion: 2026

TRIUMPH-1
TRIUMPH-2

TRIUMPH-3
TRIUMPH-4

CLBP

TRIUMPH-7
Completion: 2027

CV / RENAL OUTCOMES

TRIUMPH-OUTCOMES
Completion: 2029

HIGH-RISK MASLD

SYNERGY-OUTCOMES
Completion: 2030

WEIGHT MAINTENANCE

TRIUMPH-6
Completion: 2028

Upcoming read out

Note: Select Phase 3 trials for orforglipron and retatrutide; additional studies ongoing
OA=Osteoarthritis; OSA=obstructive sleep apnea; CLBP=Chronic Low Back Pain; CV=cardiovascular; MASLD=metabolic dysfunction-associated steatotic liver disease

Lilly Select Pipeline

October 28, 2025

TARGETS UNDISCLOSED <i>Twelve Additional NMEs</i>	UNC13A SSO (QRL-204) <i>ALS</i>
SNCA siRNA <i>Neurodegeneration</i>	VEPUGRATINIB <i>Cancer</i>
SARM1 INHIBITOR <i>Neurodegeneration</i>	SMARCA2 (BRM) <i>Cancer</i>
PNPLA3 siRNA <i>MASLD</i>	PTK7 ADC <i>Cancer</i>
PCSK9 EDITOR (VERVE-102) <i>ASCVD</i>	PI3Kα INH (STX-478) <i>Cancer</i>
NECTIN-4 ADC 2 <i>Cancer</i>	PAN KRAS <i>Cancer</i>
NAV 1.8 INH (SM) <i>Pain</i>	NECTIN-4 ADC 1 <i>Cancer</i>
MACUPATIDE <i>CMH</i>	MAPT siRNA <i>Neurodegeneration</i>
KRAS G12D <i>Cancer</i>	LA-ANP <i>Heart Failure</i>
GS INSULIN RECEPTOR AGONIST II <i>Diabetes</i>	INTEGRIN α5β1 <i>CMH</i>
GIPR AGONIST LA <i>CMH</i>	GS INSULIN RECEPTOR AGONIST <i>Diabetes</i>
FXR AG (FXR314) <i>Immunology</i>	GGG TRI-AGONIST III <i>CMH</i>
BRENIPATIDE (GIP/GLP-1 COAG III) <i>CMH</i>	FRa ADC <i>Cancer</i>
ANTI-VEGF GENE THERAPY <i>Vestibular Schwannoma</i>	AT2R ANTAGONIST <i>Pain</i>
[Ac-225]-PSMA-62 <i>Prostate Cancer</i>	ANGPTL3 EDITOR (VERVE-201) <i>ASCVD</i>

TIRZEPATIDE <i>Higher Doses</i>	TIRZEPATIDE <i>MASLD</i>
GBA1 GENE THERAPY <i>Gaucher Disease Type 1</i>	MORF-057 <i>Crohn's Disease</i>
CD19 ANTIBODY <i>Rheumatoid Arthritis</i>	ELTREKIBART <i>Ulcerative Colitis</i>
SIMEPDEKINRA <i>Psoriasis</i>	SOLBINSIRAN <i>CVD</i>
OCADUSERTIB <i>Rheumatoid Arthritis</i>	OTOF GENE THERAPY <i>Hearing Loss</i>
NAPERIGLIPRON <i>Obesity</i>	NISOTIROSTIDE <i>Diabetes</i>
MEVIDALEN <i>AD Symptomatic</i>	MORF-057 <i>Ulcerative Colitis</i>
GRN GENE THERAPY <i>Frontotemporal Dementia</i>	MAZDUTIDE ¹ <i>Obesity</i>
EPIREGULIN Ab <i>Pain</i>	GBA1 GENE THERAPY <i>Parkinson's Disease</i>
ELORALINTIDE <i>Obesity</i>	ELTREKIBART <i>Hidradenitis Suppurativa</i>
BIMAGRUMAB <i>Obesity</i>	CD19 ANTIBODY <i>Multiple Sclerosis</i>

ORFORGLIPRON <i>Osteoarthritis Pain</i>	ORFORGLIPRON <i>Stress Urinary Incontinence</i>
MIRIKIZUMAB + TIRZEPATIDE <i>CD</i>	MIRIKIZUMAB + TIRZEPATIDE <i>UC</i>
TIRZEPATIDE <i>MMO</i>	TIRZEPATIDE <i>Type 1 Diabetes</i>
SELPERCATINIB <i>Adjuvant RET+ NSCLC</i>	TIRZEPATIDE <i>CV Outcomes</i>
RETATRUTIDE <i>CV / Renal Outcomes</i>	RETATRUTIDE <i>Diabetes</i>
PIRTOBRUTINIB <i>R/R MCL Monotherapy</i>	RETATRUTIDE <i>CLBP</i>
PIRTOBRUTINIB <i>1L CLL Monotherapy</i>	PIRTOBRUTINIB <i>R/R CLL Combination</i>
ORFORGLIPRON <i>Hypertension</i>	ORFORGLIPRON <i>Obstructive Sleep Apnea</i>
OLOMORASIB Adj KRAS G12C+ NSCLC (resected)	ORFORGLIPRON <i>Diabetes</i>
OLOMORASIB 1L KRAS G12C+ NSCLC (PD-L1 high)	OLOMORASIB Adj KRAS G12C+ NSCLC (unresected)
LEBRIKIZUMAB <i>AR (perennial allergens)</i>	LEBRIKIZUMAB <i>CRSwNP</i>
IXEKIZUMAB + TIRZEPATIDE <i>PsA</i>	IXEKIZUMAB + TIRZEPATIDE <i>Psoriasis</i>
DONANEMAB <i>Preclinical Alzheimer's Disease</i>	IMLUNESTRANT <i>Adjuvant Breast Cancer</i>
RETATRUTIDE <i>Obesity, OA, OSA</i>	MUVALAPLIN <i>ASCVD</i>
ORFORGLIPRON <i>Obesity</i>	REMTERNETUG <i>Preclinical / MCI AD</i>
LEPODISIRAN <i>ASCVD</i>	OLOMORASIB 1L KRAS G12C+ NSCLC (All PD-L1)

NME

NILEX / Other

UPDATES SINCE AUGUST 5, 2025

REMOVAL

ADDITION OR MILESTONE ACHIEVED



P2X7 INHIBITOR
Pain

ABEMACICLIB
MBC Sequencing

TIRZEPATIDE
Heart Failure pEF

INSULIN EFSITORA ALFA
Diabetes

IMLUNESTRANT
ER+ HER2- mBC

¹China development with Innovent



Potential Key Events 2025

 NEW SINCE LAST UPDATE

PHASE 3 INITIATIONS

- ✓+ Orforglipron for hypertension and overweight or obesity
- ✓+ Olomorasib for resected adjuvant NSCLC¹
- ✓+ Muvalaplin for ASCVD²
- ✓+ Retatrutide for chronic low back pain and overweight or obesity
- ✓+ Olomorasib for unresected NSCLC¹
- ✓+ Tirzepatide for type 1 diabetes
- ✓+ Orforglipron for OA³ pain of the knee and overweight or obesity

Retatrutide and Tirzepatide for MASLD⁴

- ✓+ Orforglipron for SUI⁵ and overweight or obesity

Brenipatide for AUD⁶

PHASE 3 DATA DISCLOSURES

- ✓+ Orforglipron for obesity [ATTAIN-1 ✓+ / 2 ✓+]
- ✓+ Orforglipron for type 2 diabetes [ACHIEVE-1 ✓+ / 2 ✓+ / 3 ✓+ / 5 ✓+]
- ✓+ Tirzepatide cardiovascular outcomes [SURPASS-CVOT]
- ✓+ Pirtobrutinib 1L CLL vs. BR⁷ [BRUIN CLL-313]
- ✓+ Pirtobrutinib 1L CLL vs. ibrutinib [BRUIN CLL-314]

Retatrutide for OA³ pain of the knee and overweight or obesity [TRIUMPH-4]

REGULATORY SUBMISSIONS

Insulin efsitora alfa for type 2 diabetes [US ✓+ / EU ✓+ / J]

Orforglipron for obesity [US/EU/J]

Tirzepatide for cardiovascular outcomes [US]

- ✓+ Pirtobrutinib CLL full approval [US ✓+]

Pirtobrutinib for 1L CLL [US/EU]

- ✓+ Tirzepatide for Pediatric and Adolescent type 2 diabetes [US ✓+/ EU ✓+]

REGULATORY ACTIONS

- ✓+ Mirikizumab for Crohn's disease [US ✓+ / EU ✓+ / J ✓+]

Tirzepatide for HfPEF [US ✓- /EU]

Immunestrant ER+, HER2- mBC [US ✓+ / J]

Pirtobrutinib for CLL full approval [US / EU ✓+ / J]

- ✓+ Donanemab for early Alzheimer's disease [EU]

¹ Non-small cell lung cancer; ² Atherosclerotic cardiovascular disease; ³ Osteoarthritis; ⁴ Metabolic dysfunction-associated steatotic liver disease; ⁵ Stress Urinary Incontinence; ⁶ Alcohol use disorder; ⁷ Bendamustine plus Rituximab



Supplemental Slides

2025 Income Statement – Reported

Dollars in millions; except per share data

	Q3 2025	Change
TOTAL REVENUE	\$17,601	54%
GROSS MARGIN	82.9%	1.9pp
TOTAL OPERATING EXPENSE*	\$7,227	(7)%
OPERATING INCOME	\$7,365	NM
OPERATING MARGIN	41.8%	28.5pp
OTHER INCOME (EXPENSE)	\$(133)	NM
EFFECTIVE TAX RATE	22.8%	(16.1)pp
NET INCOME	\$5,583	NM
EPS	\$6.21	NM

* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)

NM = not meaningful

EPS Reconciliation

	Q3 2025	Q3 2024	% Change
EARNINGS PER SHARE (REPORTED)	\$6.21	\$1.07	NM
U.S. TAX LAW CHANGE	0.39	-	NM
ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES	0.36	0.07	NM
AMORTIZATION OF INTANGIBLE ASSETS	0.11	0.12	(8)%
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	(0.04)	(0.09)	(56)%
EARNINGS PER SHARE (NON-GAAP)	\$7.02	\$1.18	NM
ACQUIRED IPR&D	\$0.71	\$3.08	(77)%

Numbers may not add due to rounding; see slide 21 for more details on these adjustments; NM = not meaningful

Q3 Non-GAAP Adjustments

Q3 2025 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:


- income taxes related to US tax law changes effective July 4, 2025, totaling \$350.3 million, or \$0.39 per share
- asset impairment, restructuring and other special charges totaling \$364.9 million (pre-tax), or \$0.36 per share (after-tax)
- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$119.2 million (pre-tax), or \$0.11 per share (after-tax)
- net gains on investments in equity securities totaling \$48.0 million (pre-tax), or (\$0.04) per share (after-tax)

Q3 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$139.4 million (pre-tax), or \$0.12 per share (after-tax)
- asset impairment, restructuring and other special charges totaling \$81.6 million (pre-tax), or \$0.07 per share (after-tax)
- net gains on investments in equity securities totaling \$103.0 million (pre-tax), or (\$0.09) per share (after-tax)

Q3 2025 Mounjaro Sales Increased \$3.4B

\$ in Millions




Source: IQVIA NPA TRx 3MMA, weekly data September 26, 2025; RA = rolling average
TRx data is representative of the injectable incretin type 2 diabetes market



Q3 2025 Zepbound Sales Increased \$2.3B

\$ in Millions




¹ Japan and Canada marketing authorization approved for obesity under the brand name Zepbound

Source: IQVIA NPA TRx 3MMA, weekly data September 26, 2025; RA = rolling average
TRx data is representative of the branded anti-obesity market



Q3 2025 Verzenio Sales Increased 7%

\$ in Millions



Source: IQVIA NPA TRx 3MMA, weekly data September 26, 2025; RA = rolling average

Select Trials – Donanemab

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)	Apr 2023	Nov 2028
NCT05738486¹	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	1100	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2027
NCT05508789	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2028	July 2028
NCT05026866	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2996	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Nov 2027	Nov 2027

¹ clinicaltrials.gov update in progress * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Imlunestrant

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	874	Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)	Jun 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lebrikizumab

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	360	Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥ 2 points from Baseline	Dec 2025	Dec 2026
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	310	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Dec 2027	Apr 2029
NCT06280716	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia)	3	301	Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) $\geq 75\%$ Reduction in EASI Score for Mono Cohort	Sep 2025	Aug 2026
NCT06339008	Perennial Allergic Rhinitis (PAR)	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Sep 2026	Oct 2028
NCT06921759	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch)	3	206	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥ 2 -point Improvement from Baseline	Jul 2026	Sep 2026
NCT06338995	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	May 2027	Mar 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lepodisiran

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD) ¹	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	16700	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

¹ Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Mirikizumab

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Dec 2026
NCT06937099	Crohn's Disease	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction	May 2028	May 2028
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027
NCT06937086	Ulcerative Colitis	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Muvalaplin

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07157774	Elevated Lp(a)	Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) – (MOVE-Lp(a))	3	10450	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2031	Mar 2031

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Olomorasib

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06119581 J3M-MC-JZQB	Carcinoma, Non-Small-Cell Lung	A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)	3	1016	Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)	Oct 2026	Oct 2029
NCT06890598¹ J3M-MC-JZQH	Carcinoma, Non-Small-Cell Lung	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment	May 2029	Feb 2032
NCT04956640² J3M-OX-JZQA	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1 2	540	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Apr 2027	Apr 2027

¹ Also lists AstraZeneca; ² Also lists Merck Sharp & Dohme LLC

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05803421	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2749	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Mar 2026	Mar 2026
NCT06948422	Hypertension	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension)	3	974	Change from baseline in systolic blood pressure	Sep 2027	Sep 2027
NCT05869903	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3127	Mean Percent Change from Baseline in Body Weight	Jul 2025	Oct 2027
NCT06584916	Obesity	A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)	3	300	Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5	Jan 2026	Jan 2026
NCT06672939	Obesity	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	125	Percent Change from Baseline in Body Mass Index (BMI)	Feb 2027	Mar 2027
NCT06972472	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	3	600	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2027	Aug 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06972459	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	3	600	Percent Change from Baseline in Body Weight	Jan 2027	Aug 2027
NCT06649045	OSA	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
NCT07153471	Osteoarthritis	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN)	3	800	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Apr 2028	May 2028
NCT07202884	Stress Urinary Incontinence	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI)	3	1000	Change from Baseline in Incontinence Episode Frequency (IEF)	Mar 2028	Mar 2028
NCT06824051	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight	1	120	Percent Change from Baseline in Visceral Adipose Tissue (VAT)	Dec 2025	Dec 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)	Aug 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	309	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jul 2025	Aug 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Apr 2026	Jan 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314)	3	662	Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1	Jun 2025	Jan 2028
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07162181	Non-Hodgkin Lymphoma	Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers	2	13	Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events	May 2030	May 2030
NCT06721013	Immune Thrombocytopenia (ITP)	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1 2	58	Ph. 1 -Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2026	Feb 2027

Select Trials – Remternetug

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05463731	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	1667	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Apr 2024	Mar 2026
NCT06653153	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1400	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)	Apr 2029	Oct 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05929066	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2300	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
NCT05929079	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
NCT05882045	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Apr 2026	May 2026
NCT05931367	Obesity	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)	3	405	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Dec 2025	Dec 2025
NCT06383390	Obesity	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)	3	10000	Time to First Occurrence of Composite Endpoints	Feb 2029	Feb 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06662383	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight	Dec 2026	Dec 2026
NCT06859268	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	643	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2026	Feb 2026
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2026	Oct 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2026	Jan 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07035093	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)	3	586	Percent Change from Baseline in Body Weight Change from Baseline in Pain Intensity Per Numeric Rating Scale	Sep 2027	Sep 2027
NCT05936151	Chronic Kidney Disease	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	2	146	Change from Baseline in Glomerular Filtration Rate (mGFR)	Nov 2025	Nov 2025
NCT06982846	Type 2 Diabetes Mellitus	A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia	1	78	Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL)	May 2026	May 2026
NCT06982859	Diabetes Mellitus	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	1	95	Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo	Nov 2026	Nov 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retevmo

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)	May 2023	Jun 2030
NCT03157128	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1 2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment	Feb 2025	Feb 2027
NCT04819100	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population	Jan 2026	May 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Taltz

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06588283	Psoriasis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	250	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction	Dec 2025	May 2026
NCT06588296	Psoriatic Arthritis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	250	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Nov 2025	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06047548	Obesity	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
NCT06075667	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	May 2026	Jul 2029
NCT06439277	Obesity	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2027	Dec 2030
NCT05556512	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027
NCT06914895	Type 1 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	3	905	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2027	May 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06962280	Type 1 Diabetes	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	3	465	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2027	Dec 2027
NCT06037252	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026
NCT05536804	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D	Sep 2026	Oct 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Verzenio

Source: clinicaltrials.gov, October 17, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997 ¹	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
NCT05169567	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Feb 2026

¹ Also lists NSABP Foundation Inc

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Brenipatide (GIP/GLP-1 Coagonist III)	NCT06606106	Healthy	A Study of LY3537031 in Overweight, Obese, and Healthy Participants	1	302	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2026	Jul 2026
Bimagrumab	NCT07030127	Healthy	A Study of LY3985863 in Healthy Participants	1	24	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2026	Apr 2026
Bimagrumab	NCT06643728	Obesity	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	240	Percent Change from Baseline in Body Weight	Apr 2026	Jan 2027
Eloralintide	NCT06230523	Obesity	A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight	2	263	Percent Change from Baseline in Body Weight	May 2025	August 2025
Eloralintide	NCT06603571	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	350	Percent Change from Baseline in Body Weight	Jun 2026	Aug 2026
GGG Tri-Agonist III	NCT06945419	Healthy	A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	1	165	Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration	Apr 2026	Apr 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GS Insulin Receptor Agonist ¹	NCT06280703	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	70	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Oct 2026	Oct 2026
LA-ANP	NCT06148272	Healthy	A Study of LY3971297 in Healthy Participants	1	225	Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2025	Dec 2025
Macupatide	NCT06557356	Obesity	A Study of LY3532226 in Participants With Obesity	1	129	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2025	Nov 2025
Nisotirostide	NCT06897475	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2026	Jan 2027
Naperiglipron	NCT06683508	Obesity	A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight	2	275	Percent Change from Baseline in Body Weight	Apr 2026	Sep 2026
PNPLA3 siRNA	NCT05395481	Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2026	Oct 2026

¹ clinicaltrials.gov update in progress

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
ANGPTL3 EDITOR (VERVE-201)	NCT06451770	Hypercholesterolemia	Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia	1	36	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Mar 2027	Mar 2027
PCSK9 EDITOR (VERVE-102)	NCT06164730	Heterozygous Familial Hypercholesterolemia	A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease	1	36	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Aug 2026	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD19 Antibody	NCT06220669	Multiple Sclerosis	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	2	200	Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions	Aug 2027	Aug 2028
CD19 Antibody	NCT06859294	Rheumatoid Arthritis	A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis	2	40	Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP)	Feb 2026	Sep 2026
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	352	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Sep 2025	Aug 2026
Eltrekibart	NCT06598943	Ulcerative Colitis	A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	140	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
MORF-057	NCT05611671	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC (EMERALD-2)	2	282	Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026
MORF-057	NCT07186101	Ulcerative Colitis	LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis (TOPAZ-UC)	2	252	Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)	May 2027	Mar 2029
MORF-057	NCT06226883	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)	2	210	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	Nov 2026	Aug 2028
Ocadusertib ¹	NCT05848258	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

¹ Also lists Rigel Pharmaceuticals

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neuroscience

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Anti-VEGF Gene Therapy	NCT06517888	Vestibular Schwannoma	Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma	1 2	27	AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device)	Aug 2029	Aug 2029
Epiregulin Ab	NCT06568042	Neuropathic Pain	Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	2	450	Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)	Jun 2026	Sep 2026
GBA1 Gene Therapy	NCT04127578	Parkinson's Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1 2	20	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
GBA1 Gene Therapy	NCT05487599	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1 2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Oct 2030	Oct 2030
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1 2	30	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Apr 2030	Apr 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neuroscience (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
MAPT siRNA	NCT06297590	Alzheimer's Disease	A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	1	32	Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2027	Feb 2027
Mazdutide	NCT06817356	Alcohol Use Disorder	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder	2	300	Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method	Aug 2026	Aug 2026
Mevidalen	NCT06538116	Alzheimer's Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	Dec 2025	Jan 2026
OTOF Gene Therapy	NCT05821959	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1 2	18	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
SNCA siRNA	NCT06565195	Parkinson's Disease	A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (PROSPECT)	1	108	Incidence of Serious Adverse Events (SAEs)	May 2029	May 2029
UNC13A SSO (QRL-204)	NCT07100119	Amyotrophic Lateral Sclerosis	A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis	1	32	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2027	Sep 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
225Ac-PSMA-62	NCT06229366	Prostate Cancer	[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)	1	142	Maximum tolerated dose (MTD), Phase 1a: Incidence of dose limiting toxicities (DLTs)	Sep 2027	Dec 2032
VEPUGRATINIB	NCT05614739	Urinary Bladder Neoplasms	A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)	1	535	Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2027	Jun 2027
Fra ADC	NCT06400472	Ovarian Neoplasms	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	1	360	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156, Number of participants with dose-limiting toxicities (DLTs)	Feb 2027	Apr 2027
KRAS G12D	NCT06586515	Pancreatic Ductal Adenocarcinoma	A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01)	1	630	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Mar 2029	Mar 2029
Nectin-4 ADC 1	NCT06238479	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)	1	490	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Mar 2027	Mar 2027
Nectin-4 ADC 2	NCT06465069	Metastatic Solid Tumor	A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors	1	420	Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031	May 2027	May 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology (Cont.)

Source: clinicaltrials.gov, October 17, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
PAN KRAS	NCT06607185	Pancreatic Ductal Adenocarcinoma	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	1	750	Number of Participants with Dose-limiting Toxicities (DLTs)	Jan 2030	Jan 2030
SMARCA2 (BRM)	NCT06561685	Metastatic Solid Tumor	A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	1	340	Phase 1a: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)	Oct 2027	Oct 2027
PI3Kα INH (STX-478)	NCT05768139	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1)	1 2	720	Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)	Jul 2030	Jul 2030
PTK7 ADC	NCT07046923	Carcinoma, Non-Small-Cell Lung	A Study of LY4175408 in Participants With Advanced Cancer	1	240	Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408	Jul 2030	Jul 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.